Technology Partners
VC Fund
Palo Alto, United States
Technology Partners is a venture capital firm specialized in seed-, early-, and later-stage venture and private equity investments.
- Total investments:
- 58
- Last investment:
- Lead investor:
- 12%
- Fund size:
- $300M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Technology Partners invests in
Stages Technology Partners invests in
Countries Technology Partners invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series B
- $5M–$30M
- Series C
- $11M–$54M
Investment Focus
Industry
- Health Care 11 (19%)
- Biotechnology 8 (14%)
- Medical 6 (10%)
- Software 6 (10%)
- Energy 4 (7%)
Stage
- Series B 12 (21%)
- Series C 12 (21%)
- Funding Round 8 (14%)
- Series A 5 (9%)
- Series D 5 (9%)
Country
- United States 30 (52%)
- Pakistan 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Ira Ehrenpreis
General Partner
|
General Partner | Total investments: 14 | Find email | |
Marc van den Berg
General Partner
|
General Partner | Total investments: 24 | Find email | |
Sheila Mutter
General Partner and CFO
|
General Partner and CFO | Total investments: 0 | Find email | |
Ted Ardell
General Partner
|
General Partner | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Benvenue Medical, Inc. is developing innovative, minimally invasive surgical solutions to treat spinal disorders. The company is privately held and funded by CRG Partners. | $23M / Series F / Jan 07, 2016 | ||
| Elcelyx was founded in 2010 with venture capital backing based on Gut Sensory Modulation (GSM) technology. Elcelyx’s proprietary, first-in-class Gut Sensory Modulators are delivered directly to the lower gut where they act on molecular targets to elicit physiological and pharmacological effects. The Elcelyx proprietary product candidate, NewMetfor Type 2 diabetes is entering Phase 2b development and is a blockbuster opportunity designed to address the unmet needs in the oral anti-diabetic market.Elcelyx is led by an experienced management team and Board of Directors with track records of success in drug development and commercialization. Premier investors along with seasoned scientists and clinicians support the team. In September 2013, Elcelyx announced the formation of NaZura BioHealth Inc, a separate company established to focus on the development on non-NewMet assets.Elcelyx is headquartered in San Diego, California. | $40M / Series E / Oct 01, 2015 | ||
| Beamreach Solar is developing high-efficiency, low-cost, crystalline silicon solar cells and modules for photovoltaic (PV) electricity generation. | $70M / Series D / Aug 16, 2015 | ||
| Kaiam Is an Online Store in USA where to people can shop Ladies dresses in USA. | $35M / Venture - Series Unknown / Sep 22, 2014 | ||
| Beamreach Solar is developing high-efficiency, low-cost, crystalline silicon solar cells and modules for photovoltaic (PV) electricity generation. | $31M / Series D / Jul 21, 2014 | ||
| Benvenue Medical, Inc. is developing innovative, minimally invasive surgical solutions to treat spinal disorders. The company is privately held and funded by CRG Partners. | $40M / Series E / Jun 18, 2014 | ||
| ForSight VISION5 was founded in 2010 as the fifth company created by the ophthalmic product incubator, ForSight Labs. ForSight VISION5 is developing non-invasive products that replace eye drops and provide sustained therapy for major eye diseases including glaucoma, dry eye, and allergy. The company is currently in its second Phase 2 clinical studyfor its lead product, the Helios insert. | $15M / Series C / Apr 16, 2014 | ||
| Transcend Medical is focused on the development of medical devices for the treatment of glaucoma, a cause of adult irreversible blindness. It is estimated that nearly four million people in the US and over 60 million worldwide are afflicted with the disease today and the numbers are expected to grow to nearly six million in the US, and to over 70million worldwide by the year 2015.In 2005, Transcend Medical was the first company to spin out of ForSight Labs, an incubator solely focused on ophthalmic innovations. Transcend Medical was granted CE mark for the CyPass Micro-Stent® in 2008, and is being evaluated in several clinical studies in the US and abroad, including the COMPASS multi-center clinical trial. | $29M / Series C / Apr 02, 2014 | ||
| Elcelyx was founded in 2010 with venture capital backing based on Gut Sensory Modulation (GSM) technology. Elcelyx’s proprietary, first-in-class Gut Sensory Modulators are delivered directly to the lower gut where they act on molecular targets to elicit physiological and pharmacological effects. The Elcelyx proprietary product candidate, NewMetfor Type 2 diabetes is entering Phase 2b development and is a blockbuster opportunity designed to address the unmet needs in the oral anti-diabetic market.Elcelyx is led by an experienced management team and Board of Directors with track records of success in drug development and commercialization. Premier investors along with seasoned scientists and clinicians support the team. In September 2013, Elcelyx announced the formation of NaZura BioHealth Inc, a separate company established to focus on the development on non-NewMet assets.Elcelyx is headquartered in San Diego, California. | $24.7M / Series C / Feb 20, 2014 | ||
| Kaiam Is an Online Store in USA where to people can shop Ladies dresses in USA. | $20M / Aug 27, 2013 | ||
| See all 58 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Technology Partners invest in?
Technology Partners invests primarily in Health Care, Biotechnology and Medical startups, most often at Series B and Series C stage. Most of the 58 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Technology Partners's check size?
Technology Partners typically joins rounds of $5M–$30M at Series B and $11M–$54M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Technology Partners participates in.
How do I contact Technology Partners?
Public channels for Technology Partners include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Technology Partners?
The team at Technology Partners includes Ira Ehrenpreis (General Partner), Marc van den Berg (General Partner) and Sheila Mutter (General Partner and CFO). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
